Apoptosis is characterized by cell shrinkage caused by disruption of the maintenance of the normal physiological concentrations of K+ and Na+ and intracellular ion homeostasis. impedes effective TRAIL therapy, and an innovative approach that can override TRAIL resistance is definitely urgently required. Apoptosis is characterized by cell shrinkage caused by disruption of the maintenance of the normal physiological concentrations of K+ and Na+ and intracellular ion homeostasis. The disrupted ion homeostasis prospects to depolarization and apoptosis. Recent evidence suggests XMD 17-109 that depolarization is an early and prerequisite event during TRAIL-induced apoptosis. Moreover, diverse natural products and synthetic chemicals capable of depolarizing the cell membrane show tumor-selective killing and TRAIL-sensitizing effects. Here, we discuss the part of depolarization in selective killing of malignancy cells in connection with the emerging concept that oxidative stress is a critical mediator of mitochondrial and endoplasmic reticulum dysfunctions and serves as a tumor-selective target in malignancy treatment. mediated p53 Ser15Hu et al. (123)PhosphorylationBax increase and translocationWogoninAnti-cancer agentProstate cancerApoptosisH2O2mediated upregulation of p53 and PumaLee et al. (50)KCl/U37883A/glibenclamidePMDMelanoma, leukemia, lung cancerApoptosisMitochondrial through these Bax/Bak megachannels into the cytosol induces assembly of the apoptosome, representing the activation-platform for another initial caspase, caspase-9. Activated caspase-9 also promotes the activation of caspase-3/6/7, thereby providing a positive loop for caspase activation (3). Unlike TNF-, TRAIL has been shown to induce apoptosis in malignancy cells with minimal cytotoxicity toward non-transformed cells (4), although under particular conditions, it enhances the cytotoxicity of several medicines to hepatocytes/liver and mast cells (5C9). Therefore, TRAIL is definitely a encouraging agent in malignancy treatment with high selectivity. However, different malignancy cell types such as malignant melanoma, glioma, XMD 17-109 and non-small cell lung malignancy (NSCLC) cells are resistant to TRAIL treatment despite expressing DRs on their cell surface. Moreover, TRAIL-responsive tumors acquire a resistant phenotype that renders TRAIL therapy ineffective (10). Therefore, overcoming TRAIL resistance is necessary for effective TRAIL therapy, and small molecules that can potentiate TRAIL performance are urgently required. Recently, much progress has been made in restorative treatment with TRAIL-related substances. Recombinant human TRAIL (rhTRAIL) or agonist monoclonal antibodies (mAbs) against DR4/DR5, collectively referred as to pro-apoptotic receptor agonists (PARAs), have been subjected to medical trials for a variety of malignancy cell types, including malignant melanoma and NSCLC cells. In addition, varied chemical substances including ABT-737 XMD 17-109 and SM-164 are expected to potentiate the intrinsic death pathway by antagonizing natural inhibitors such as FLICE inhibitory protein, Bcl-2, Mcl-1, and survivin (11). Some recent medical tests possess shown the security FLT1 and effectiveness of combined treatments with PARAs and standard genotoxic medicines, while the results of additional medical tests were disappointing and showed only moderate performance. PARAs such XMD 17-109 as dulanermin (rhTRAIL), mapatumumab (anti-DR4 mAb), conatumumab, CS-1008, or “type”:”entrez-protein”,”attrs”:”text”:”PRO95780″,”term_id”:”1357785992″,”term_text”:”PRO95780″PRO95780 (anti-DR5 mAb), in combination with paclitaxel, carboplatin, or bevacizumab [anti-vascular endothelial growth factor (VEGF) mAb] were tested for their effects toward NSCLC patients in a randomized phase II trial, but showed only modest effects (11). Thus, induction of apoptosis by the intrinsic pathway does not appear to be a suitable target in the treatment of TRAIL-resistant malignancy cells. Dual Function of Depolarization in the Regulation of Apoptosis Apoptosis is usually a fundamental physiological process characterized by the loss of cell volume (cell shrinkage), chromatin condensation, and internucleosomal DNA fragmentation. Cell shrinkage is usually a hallmark of apoptosis, which is usually caused by disruption of the maintenance of normal physiological concentrations of K+ and Na+ and intracellular ion homeostasis (12, 13). Loss of these monovalent ions has been reported to facilitate the loss XMD 17-109 of cell volume (apoptotic volume decrease) and caspase-3 activation (13). Cell shrinkage requires ion transport activity across the cell membrane, including.